Literature DB >> 377491

Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor.

R F Casper, S S Yen.   

Abstract

Subcutaneous injection of 50 micrograms of a long-acting analog of luteinizing hormone-releasing factor on each of two successive days during mid-luteal phase in normally cycling women induced a short luteal phase and premature menstruation. These events were associated with luteolysis, as evidenced by the consistent and parallel premature decline of progesterone and estradiol levels compared with those in control cycles. This finding may prove to be useful in the prevention or interception of implantation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 377491     DOI: 10.1126/science.377491

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  21 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

2.  LRFD6a has a dose-related stimulatory or inhibitory effect on the ovary in normal luteal phase women.

Authors:  E R Barnea; R Maheux; B V Caldwell; J DeFazio; A H DeCherney; F Naftolin
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

Review 3.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

4.  Inadvertent exposure of early pregnancy to gonadotropin releasing hormone analogue.

Authors:  A Shulman; M Shilon; C Bahary; J Dor; A Ellenbogen; S Mashiach
Journal:  J Assist Reprod Genet       Date:  1993-07       Impact factor: 3.412

Review 5.  GnRH and its analogues. Current therapeutic applications and new prospects.

Authors:  H M Fraser
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

Review 6.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

7.  Similar luteinizing hormone-releasing hormone binding sites in rat anterior pituitary and ovary.

Authors:  J J Reeves; C Séguin; F A Lefebvre; P A Kelly; F Labrie
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

Review 8.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

9.  Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Authors:  Ya-Qin Wang; Jin Luo; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jin Yang
Journal:  J Ovarian Res       Date:  2015-09-23       Impact factor: 4.234

10.  Comparison between depot leuprorelin and daily buserelin in IVF.

Authors:  E Porcu; M Filicori; L Dal Prato; R Fabbri; R Seracchioli; C Colombi; C Flamigni
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.